The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Glycogen synthase kinase-3 beta (GSK-3β) blockade with 9-ing-41 in gastrointestinal cancers: The 1801 phase Ib/II study.
 
Howard Safran
No Relationships to Disclose
 
Mallika Sachdev Dhawan
No Relationships to Disclose
 
Ludimila Cavalcante
No Relationships to Disclose
 
Andre Luiz De Souza
No Relationships to Disclose
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Vyriad (Inst); Vyriad (Inst); Vyriad (Inst); Vyriad (Inst)
 
Daniel D. Billadeau
Stock and Other Ownership Interests - Actuate Therapeutics; Actuate Therapeutics; Actuate Therapeutics; Actuate Therapeutics
 
Francis J. Giles
Employment - Actuate Therapeutics; Actuate Therapeutics; Actuate Therapeutics; Actuate Therapeutics
Leadership - Epigene Therapeutics; Epigene Therapeutics; Epigene Therapeutics; Epigene Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics; Actuate Therapeutics; Actuate Therapeutics; Actuate Therapeutics
 
Pamela N. Munster
Leadership - Alessa Therapeutics; Alessa Therapeutics; Alessa Therapeutics; Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; Alessa Therapeutics; Alessa Therapeutics; Alessa Therapeutics
Honoraria - AtlasMedx; AtlasMedx; AtlasMedx; AtlasMedx; Celgene; Celgene; Celgene; Celgene; CStone Pharmaceuticals; CStone Pharmaceuticals; CStone Pharmaceuticals; CStone Pharmaceuticals; Epigene; Epigene; Epigene; Epigene; McVeigh; McVeigh; McVeigh; McVeigh; Prometheus (I); Prometheus (I); Prometheus (I); Prometheus (I); Xynomic Pharma (Inst); Xynomic Pharma (Inst); Xynomic Pharma (Inst); Xynomic Pharma (Inst)
Consulting or Advisory Role - HUYA Bioscience International; HUYA Bioscience International; HUYA Bioscience International; HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Andes Biotechnologies (Inst); Andes Biotechnologies (Inst); Andes Biotechnologies (Inst); Biomarin (Inst); Biomarin (Inst); Biomarin (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Immune Design (Inst); Immune Design (Inst); Immune Design (Inst); Intellikine (Inst); Intellikine (Inst); Intellikine (Inst); Intellikine (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); Onconova Therapeutics (Inst); oncosec (Inst); oncosec (Inst); oncosec (Inst); oncosec (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Piramal Life Science (Inst); Piramal Life Science (Inst); Piramal Life Science (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Plexxikon (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents; UCSF patent on using silastic implants to deliver anticancer agents; UCSF patent on using silastic implants to deliver anticancer agents; UCSF patent on using silastic implants to deliver anticancer agents
 
Benedito A. Carneiro
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Actuate Therapeutics (Inst); Actuate Therapeutics (Inst); Actuate Therapeutics (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)